77
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Precision Diagnostics - academia, biotech, pharma - collaboration is key

      Published
      conference-abstract
        1 , , 1 , 1 , 1
      RExPO24 Conference
      REPO4EU
      RExPO24
      3-5 July 2024
      Precision Diagnostics, Precision Medicine, Biomarkers, Biomarker Signatures, Mechanism-based Medicine, Protein Profiling, scioDiscover platform
      Bookmark

            Abstract

            Precision Diagnostics is a pre-requisite for Precision Medicine by enabling a characterization of diseases on a molecular level and stratification of patients leading to mechanism-based treatment. Collaborative approaches in identifying, verifying and validating are required to enable a faster pace for the development of innovative new biomarker signatures.

            In order to quickly development these markers, collaboration between academia, biotech and pharma companies is of high importance. Sciomics holds a unique position as we work with all parties involved, bridge gaps, speed up sample procurement, connect researchers and provide fast and highly sensitive analyses using our in-house scioDiscover platform to identify and verify new biomarkers. Sciomics spans the whole development pipeline for biomarkers and drives this forward in the research setting as well as for its own commercial biomarker development projects.

            To find the ideal biomarker for each disease, new biomarker candidates can be derived from all kinds of biological samples such as plasma/serum, spinal fluid (CSF), cells such as PBMCs, buffy coats or single immune cell populations. Selecting the ideal sample type can yield significant advantages, e.g. not having to rely on CSF but instead use markers measured in plasma or serum samples as these are far easier to obtain and the procedure for getting plasma is far less invasive and less costly compared to CSF.

            Next to classical diagnostic biomarkers, biomarkers can also be used to predict disease trajectories e.g. whether hospitalization is required, disease severity1 or treatment response in various disease areas such as infectious or neurodegenerative diseases and organ damage while also yielding information about the disease mechanisms.

            Leveraging the biomarker development pipeline used at Sciomics in collaboration with academic groups, biotech and pharma partners can yield ideal biomarker candidates in a much faster fashion to further Precision Diagnostics for Precision Medicine.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            8 May 2024
            Affiliations
            [1 ] Sciomics GmbH, Neckargemünd, Germany;
            Author notes
            Author information
            https://orcid.org/0009-0002-5173-8649
            Article
            10.58647/REXPO.24000056.v1
            4336a899-5c4b-42c0-a274-734513d0427c

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 8 May 2024
            Funding
            Funded by: funder-id http://dx.doi.org/10.13039/100018696, HORIZON EUROPE Health;
            Award ID: 101057619
            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Cell biology,Quantitative & Systems biology,Molecular medicine,Cancer biology,Molecular biology,Neurosciences,Life sciences
            Precision Medicine,Biomarker Signatures,Mechanism-based Medicine,Precision Diagnostics,Biomarkers,scioDiscover platform,Protein Profiling

            Comments

            Comment on this article